Pegcetacoplan and the C3 Complement Mechanism

Pegcetacoplan is a targeted inhibitor of complement component C3 — the central convergence point of all three complement activation pathways — and its dual approval as Syfovre (geographic atrophy) and Empaveli (paroxysmal nocturnal hemoglobinuria) makes it the most therapeutically versatile complement asset in the current rare disease landscape. By binding C3 and its activation fragment C3b, pegcetacoplan prevents downstream amplification of complement-mediated tissue damage before the terminal membrane attack complex is assembled.

The strategic significance of acting at C3 rather than C5 is considerable. Inhibitors targeting C5 — such as eculizumab and ravulizumab — block terminal complement activation but leave C3b-mediated opsonisation and extravascular haemolysis intact. Pegcetacoplan’s upstream mechanism addresses this gap, making it relevant in conditions where C3b deposition is a primary driver of pathology, as is the case in both geographic atrophy and PNH. According to the FDA, the approval of Syfovre in 2023 marked the first time any drug had demonstrated a meaningful slowing of GA lesion growth in a randomised controlled trial.

Syfovre’s Role in Geographic Atrophy: A First-in-Class Milestone

Syfovre (pegcetacoplan intravitreal injection) became the first FDA-approved treatment for geographic atrophy secondary to age-related macular degeneration — a condition affecting millions of older adults globally and historically managed only with supportive care. Geographic atrophy is characterised by progressive, irreversible loss of retinal pigment epithelium, photoreceptors, and choriocapillaris, driven in part by localised complement dysregulation in the sub-retinal space.

The complement system’s role in AMD pathogenesis has been recognised for over two decades, with genetic studies identifying variants in complement factor H (CFH), complement factor B (CFB), and C3 itself as major risk loci for AMD progression. This genetic validation underpins the biological rationale for Syfovre’s mechanism and differentiates it from prior failed attempts to treat GA with anti-VEGF agents or neuroprotective strategies. Research published via Nature and affiliated journals has extensively characterised complement-mediated drusen formation and RPE atrophy in AMD pathogenesis.

“Syfovre represents the first time any drug demonstrated a meaningful slowing of geographic atrophy lesion growth in a randomised controlled trial — a milestone for a disease that had no approved treatment for decades.”

The commercial significance of Syfovre extends beyond its first-in-class status. Geographic atrophy affects an estimated 5 million patients in the United States and Europe combined, representing a substantial addressable market with high unmet need. For any acquirer, Syfovre’s established commercial infrastructure — including intravitreal injection clinic networks and retinal specialist relationships — represents a durable competitive asset that would take years to replicate organically. According to the NIH National Eye Institute, age-related macular degeneration is the leading cause of vision loss in adults over 50 in developed countries, reinforcing the long-term market opportunity for GA-targeted therapies.

Empaveli and the PNH Competitive Landscape

Empaveli (pegcetacoplan subcutaneous injection) is approved for paroxysmal nocturnal hemoglobinuria — a rare, life-threatening clonal disorder of haematopoietic stem cells in which the absence of GPI-anchored complement regulatory proteins (CD55 and CD59) renders red blood cells vulnerable to complement-mediated lysis. PNH has been a proving ground for complement therapeutics since eculizumab’s approval in 2007, and Empaveli’s C3-targeted mechanism provides a differentiated clinical profile.

The PNH market is well-established, with eculizumab (Soliris, AstraZeneca/Alexion) and ravulizumab (Ultomiris) having generated multi-billion dollar revenues since their respective approvals. Empaveli’s upstream C3 inhibition addresses a recognised limitation of C5-targeted therapy: the persistence of extravascular haemolysis driven by C3b opsonisation, which C5 inhibitors cannot prevent. This clinical differentiation has allowed Apellis to compete in a crowded rare haematology market by targeting a specific patient subgroup with residual anaemia on C5 inhibitors. Regulatory frameworks for rare disease drug approvals are outlined by the European Medicines Agency, which has also granted Empaveli conditional marketing authorisation in the EU.

For Biogen, the PNH indication would represent an entry into rare haematology — a therapeutic area adjacent to its core neuroscience and rare neurological disease focus. The established reimbursement pathways for PNH therapies, combined with the orphan drug designations associated with pegcetacoplan, would provide Biogen with a predictable revenue base to support broader pipeline investment in complement-mediated rare diseases.

Why the Apellis Portfolio Fits Biogen’s Rare Disease Strategy

Biogen’s strategic positioning has evolved significantly over the past decade, with the company seeking to diversify beyond its core multiple sclerosis franchise into rare neurological diseases, Alzheimer’s disease, and adjacent rare disease categories. The Apellis complement portfolio would address three strategic objectives simultaneously: commercial revenue diversification, pipeline depth in validated biology, and geographic expansion of rare disease infrastructure.

The complement system’s relevance to neurological disease is increasingly recognised. Complement-mediated synaptic pruning has been implicated in Alzheimer’s disease pathogenesis — an area where Biogen has invested heavily through lecanemab (Leqembi) — and in neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune CNS condition. Acquiring a platform with proven C3 inhibition expertise would give Biogen optionality to explore complement-targeted approaches in neurological indications where the biology intersects with its existing pipeline. The broader scientific community, as catalogued by WIPO‘s global patent database, has seen a substantial increase in complement-targeted patent filings across neurology, ophthalmology, and nephrology over the past decade.

From a commercial infrastructure perspective, Apellis has built a specialised rare disease commercial organisation with established relationships in retinal specialist and haematology/oncology networks. This infrastructure — covering intravitreal injection centres, rare disease patient advocacy engagement, and orphan drug reimbursement expertise — would substantially reduce Biogen’s time-to-scale in ophthalmology and haematology. PatSnap’s life sciences intelligence platform enables business development teams to benchmark such portfolio acquisitions against competitive complement pipeline assets in real time.

Pipeline Integration and Complement Pathway Expansion

Integrating the Apellis pipeline into Biogen’s R&D organisation would require alignment across three dimensions: scientific platform, clinical development infrastructure, and regulatory strategy. Apellis’s complement expertise extends beyond pegcetacoplan to earlier-stage assets targeting different nodes of the complement cascade, providing Biogen with a platform rather than a single-asset acquisition.

The complement therapeutics pipeline is one of the most active areas of rare disease drug development. Beyond C3 and C5 inhibition, companies are pursuing targets including factor B, factor D, factor P (properdin), C1q, and C2 — each relevant to distinct disease subsets within the complement-mediated rare disease spectrum. An acquirer with Apellis’s foundational C3 inhibition platform would be positioned to in-license or co-develop assets targeting complementary nodes, building a multi-mechanism complement franchise analogous to what Alexion (now AstraZeneca) achieved with its C5-centred portfolio. PatSnap Eureka’s drug intelligence capabilities allow R&D teams to map the full competitive complement pipeline, identify white-space opportunities, and benchmark Apellis’s IP position against emerging challengers.

From a regulatory perspective, pegcetacoplan’s existing FDA and EMA approvals in two distinct rare disease indications provide a regulatory precedent and safety database that would accelerate label expansion applications. Orphan drug designations associated with pegcetacoplan’s approved indications carry market exclusivity provisions that protect the commercial position during any post-acquisition integration period. The FDA’s Office of Orphan Products Development has established frameworks that reward investment in rare disease drug development with seven-year market exclusivity and tax incentives — provisions that would directly benefit a Biogen-Apellis combined entity.

The scientific and commercial case for complement-targeted rare disease investment is well-supported by the track record of Alexion’s complement franchise, which grew from a single PNH indication with eculizumab to a multi-indication, multi-asset portfolio generating billions in annual revenue before its acquisition by AstraZeneca. Apellis’s C3-targeted differentiation — acting upstream of the entire Alexion/AstraZeneca C5 franchise — positions a potential Biogen-Apellis entity as the leading complement platform company with coverage across the full complement cascade from C3 through the terminal pathway.